🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 52 Nanning 10 Zhongshan 8 Foshan 5 Dongguan 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University52 XIANG YANQUN3 Sichuan Baili Pharmaceutical Co., Ltd.3 Ming-Yuan Chen2 Affiliated Cancer Hospital & Institute of Guangzhou Medical University1 Clear sponsor filter
Site location
Guangzhou52 Nanning10 Zhongshan8 Foshan5 Dongguan4
All 25 locations
Target enrolment
to

Trials with a site in Guangzhou

52 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
NCT07824856Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
DrugsGemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
138
Guangzhou
2026-10
Recruiting
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NCT07584499Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
DrugBecotatug Vedotin
Sun Yat-sen University
Phase 1
51
Guangzhou
2026-05-30
Not yet open
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
NCT07540390Nasopharyngeal Carcinoma
DrugsAnlotinib·Gemcitabine·Cisplatin·Tislelizumab
Sun Yat-sen University
Phase 3
442
Guangzhou
2026-05-08
Recruiting
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
NCT06912711Nasopharyngeal Carcinoma
DrugsNimotuzumab·Tislelizumab
Sun Yat-sen University
Phase 2
70
Guangzhou
2025-05-16
Recruiting
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
NCT06851247Nasopharyngeal Carcinoma
DrugsAnlotinib·Gemcitabine·Cisplatin·Tislelizumab
Sun Yat-sen University
Phase 2
47
Guangzhou
2025-01-03
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugAdebrelimab
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
NCT06323239Nasopharyngeal Carcinoma
DrugsGemcitabine·Cisplatin·Tislelizumab
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
DrugsConcurrent chemoradiotherapy·CCRT·GP·Adebrelimab
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Not yet open
KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
NCT06370026Nasopharyngeal Carcinoma
DrugKSD-101
Sun Yat-sen University
Phase EARLY_PHASE1
12
Guangzhou
2024-05-01
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
NCT06313450Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
DrugsCapecitabine·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Active, closed
Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study
NCT06881225Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Recruiting
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
NCT06092957Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Active, closed
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
NCT05979961Nasopharyngeal Carcinoma
DrugGemcitabine and cisplatin
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugsCadonilimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
NCT05877872Nasopharyngeal Carcinoma, De-escaltion Therapy
Sun Yat-sen University
Phase 3
424
Guangzhou
2023-05-20
Recruiting
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
NCT05854849Nasopharyngeal Carcinoma
DrugsApatinib·Camrelizumab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
244
Guangzhou
2023-05-01
Not yet open
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT05780294Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
DrugsLobaplatin·Bevacizumab
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Not yet open
A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
NCT05622474Nasopharyngeal Carcinoma
Sun Yat-sen University
Not applicable
236
Guangzhou
2022-11-30
Active, closed
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
NCT05524168Nasopharyngeal Carcinoma
DrugsCamrelizumab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
41
Guangzhou
2022-11-25
Active, closed
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
NCT05531916Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sun Yat-sen University
Not applicable
182
Guangzhou
2022-11-21
Recruiting
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
NCT05447169Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Recruiting
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
NCT05352321Nasopharyngeal Carcinoma
DrugsGemcitabine·Cisplatin
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
DrugsGP·Palbociclib
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Active, closed
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
NCT05201859Nasopharyngeal Carcinoma
DrugsSintilimab·Capecitabine
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
NCT05304468Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Recruiting
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
NCT05342792Nasopharyngeal Carcinoma
DrugsCapecitabine·Tislelizumab
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
DrugTislelizumab
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Active, closed
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05193617Nasopharyngeal Carcinoma
DrugsGP·Penpulimab·Anlotinib
Sun Yat-sen University
Phase 2
104
Guangzhou
2022-01-20
Recruiting
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
NCT04436965Nasopharyngeal Carcinoma, Nutrition Therapy
DrugCisplatin
Sun Yat-sen University
Phase 3
266
Guangzhou
2021-08-16
Active, closed
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
NCT04907370Nasopharyngeal Carcinoma
DrugsGemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
Not yet open
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
NCT04890522Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
DrugsGemcitabine·Cisplatin·Tislelizumab·Bevacizumab
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
NCT04944914Nasopharyngeal Carcinoma
DrugCamrelizumab
Sun Yat-sen University
Phase 3
188
Guangzhou
2021-06-01
Recruiting
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
NCT04778956Nasopharyngeal Carcinoma, PD-1, Surgery
DrugTislelizumab
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Recruiting
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
NCT04448522Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Active, closed
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
NCT04456322Nasopharyngeal Carcinoma
DrugsNimotuzumab·Cisplatin
Sun Yat-sen University
Phase 3
381
Guangzhou
2020-08-17
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
DrugTislelizumab
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
NCT04544969Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2020-04-01
Active, closed
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
NCT04223024Nasopharyngeal Carcinoma
DrugsCCRT·Nimotuzumab
Sun Yat-sen University
Phase 2
246
Guangzhou
2020-01-31
Recruiting
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
NCT04136886Nasopharyngeal Carcinoma
DrugCisplatin
Sun Yat-sen University
Phase 3
346
Guangzhou
2020-01-01
Active, closed
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
DrugsGemcitabine and cisplatin·Cisplatin
Sun Yat-sen University
Phase 3
468
Guangzhou
2019-04-03
Active, closed
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
NCT03306121Nasopharyngeal Carcinoma
DrugCCRT
Sun Yat-sen University
Phase 3
322
Guangzhou
2017-11-13
Recruiting
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
NCT03353467Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
Sun Yat-sen University
Not applicable
228
Guangzhou, Zhongshan, Nanning
2017-10-01
Active, closed
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03047265Nasopharyngeal Carcinoma
DrugsCisplatin·Paclitaxel
Sun Yat-sen University
Phase 2
164
Guangzhou
2017-02-04
Active, closed
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
NCT02460887Nasopharyngeal Carcinoma
DrugsGemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
236
Guangzhou
2015-06
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

29 of the 52 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 52 studies
PhaseStudiesRecruitingShare
Phase 3261550%
Phase 213625%
Not applicable539.6%
Observational549.6%
Phase 1111.9%
Phase 2/3101.9%
Phase EARLY_PHASE1101.9%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sun Yat-sen University5229
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.